Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-03-25 Sale | 2026-03-27 4:57 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $35.1 | $1,404,024 | 161,268 (Direct) | View |
| 2026-03-17 Sale | 2026-03-19 5:50 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $27.76 | $138,800 | 201,268 (Direct) | View |
| 2026-03-09 Sale | 2026-03-11 5:32 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $30.07 | $1,202,638 | 397,665 (Direct) | View |
| 2026-03-06 Sale | 2026-03-10 6:15 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 10,000 | $29.58 | $295,839 | 51,000 (Direct) | View |
| 2026-02-17 Sale | 2026-02-19 6:38 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,230 | $26.18 | $32,196 | 171,865 (Indirect Direct) | View |
| 2026-02-17 Sale | 2026-02-19 6:36 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 45,000 | $26.17 | $1,177,862 | 246,268 (Direct) | View |
| 2026-02-06 Sale | 2026-02-10 6:12 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 5,000 | $29.04 | $145,219 | 740,188 (Indirect) | View |
| 2026-01-20 Sale | 2026-01-22 5:34 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 20,000 | $26.75 | $535,099 | 745,188 (Indirect) | View |
| 2026-01-20 Sale | 2026-01-22 5:33 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,230 | $26.75 | $32,902 | 173,095 (Indirect Direct) | View |
| 2026-01-09 Sale | 2026-01-13 5:54 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 48,300 | $27.99 | $1,351,762 | 215,011 (Indirect) | View |
| 2026-01-08 Sale | 2026-01-12 5:12 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 132,500 | $26.23 | $3,476,014 | 765,188 (Indirect) | View |
| 2026-01-08 Sale | 2026-01-12 5:11 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 13,920 | $25.02 | $348,281 | 148,780 (Indirect Direct) | View |
| 2025-12-19 Sale | 2025-12-23 6:45 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 5,000 | $16.84 | $84,206 | 897,688 (Indirect) | View |
| 2025-12-08 Sale | 2025-12-10 5:13 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,663 | $21.02 | $140,073 | 263,311 (Indirect) | View |
| 2025-11-19 Sale | 2025-11-21 5:28 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $22.33 | $279,155 | 902,688 (Indirect) | View |
| 2025-11-17 Sale | 2025-11-19 6:45 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $21.82 | $272,739 | 890,392 (Indirect) | View |
| 2025-11-07 Sale | 2025-11-12 5:34 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $17.4 | $116,034 | 269,974 (Indirect) | View |
| 2025-10-20 Sale | 2025-10-22 7:20 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,500 | $22.08 | $276,025 | 915,188 (Indirect) | View |
| 2025-10-17 Sale | 2025-10-21 6:13 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,500 | $21.33 | $266,654 | 902,892 (Indirect) | View |
| 2025-10-07 Sale | 2025-10-09 5:21 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 6,667 | $20.1 | $133,993 | 276,641 (Indirect) | View |
| 2025-09-29 Sale | 2025-10-01 4:46 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $20.4 | $66,291 | 128,056 (Direct) | View |
| 2025-09-26 Sale | 2025-09-30 5:53 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 4,000 | $20.25 | $81,005 | 927,688 (Indirect) | View |
| 2025-09-26 Sale | 2025-09-30 5:51 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 3,700 | $20.06 | $74,228 | 915,392 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-03-25 Exercise | 2026-03-27 4:57 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $2.48 | 161,268 (Direct) | View |
| 2026-03-25 Exercise | 2026-03-27 4:57 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $0 | 161,268 (Direct) | View |
| 2026-03-17 Exercise | 2026-03-19 5:50 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $2.48 | 201,268 (Direct) | View |
| 2026-03-17 Exercise | 2026-03-19 5:50 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 5,000 | $0 | 201,268 (Direct) | View |
| 2026-03-09 Exercise | 2026-03-11 5:32 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $2.48 | 397,665 (Direct) | View |
| 2026-03-09 Exercise | 2026-03-11 5:32 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 40,000 | $0 | 397,665 (Direct) | View |
| 2026-02-17 Exercise | 2026-02-19 6:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 45,000 | $2.48 | 246,268 (Direct) | View |
| 2026-02-17 Exercise | 2026-02-19 6:36 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 45,000 | $0 | 246,268 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 8:01 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 17,126 | $0 | 17,126 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 8:00 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 19,234 | $0 | 19,234 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:59 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director | 35,569 | $0 | 35,569 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:57 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Garland J. Scott Director | 1,427 | $0 | 1,427 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:56 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 17,126 | $0 | 17,126 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:56 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 17,126 | $0 | 17,126 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:55 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 17,126 | $0 | 17,126 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:53 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 140,000 | $0 | 355,011 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:52 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 131,250 | $0 | 871,438 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:49 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 175,000 | $0 | 211,000 (Direct) | View |
| 2026-02-12 Option Award | 2026-02-17 7:47 pm | N/A 2036-02-12 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 175,000 | $0 | 175,000 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 6:10 pm | N/A 2036-01-07 | Enliven Therapeutics Inc. | ELVN | Garland J. Scott Director | 59,372 | $0 | 59,372 (Direct) | View |
Ownership | 2026-01-09 6:04 pm | N/A 2034-09-26 | Enliven Therapeutics Inc. | ELVN | Garland J. Scott Director | 0 | $0 | 26,580 (Direct) | View |
| 2025-12-22 Exercise | 2025-12-23 6:47 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 13,000 | $2.48 | 128,056 (Direct) | View |
| 2025-12-22 Exercise | 2025-12-23 6:47 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 13,000 | $0 | 128,056 (Direct) | View |
| 2025-12-17 Exercise | 2025-12-19 5:58 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 15,958 | $0 | 65,625 (Direct) | View |
| 2025-12-17 Exercise | 2025-12-19 5:58 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 15,958 | $1.12 | 65,625 (Direct) | View |
| 2025-12-11 Option Award | 2025-12-12 6:31 pm | N/A 2035-12-11 | Enliven Therapeutics Inc. | ELVN | Fair Richard A. PRESIDENT AND CEO | 875,000 | $0 | 875,000 (Direct) | View |
| 2025-09-29 Exercise | 2025-10-01 4:46 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 128,056 (Direct) | View |
| 2025-09-29 Exercise | 2025-10-01 4:46 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 128,056 (Direct) | View |